Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

February 8, 2019

Over the last 8 years helped lead the charge of new targeted therapies in chronic lymphocytic leukemia with the approval of ibrutinib. Ibrutinib is the first in class FDA approved oral targeted therapy that blocks the B cell receptor (BCR) by tightly binding downstream to Bruton’s Tyrosine Kinase (BTK) and